Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AMSTERDAM--(BUSINESS WIRE)--Stryker announced the completion of the first European surgeries using the Infinity Total Ankle System with Adaptis and Everlast technology.

First Surgeries Using Stryker's Infinity With Adaptis and Everlast Successfully Completed in Europe

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increase, with earnings and revenues beating their respective estimates.

Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised

Start Time: 16:30 January 1, 0000 5:28 PM ET Stryker Corporation (NYSE:SYK ) Q1 2024 Earnings Conference Call April 30, 2024, 16:30 PM ET Company Participants Kevin Lobo - Chair and CEO Glenn Boehnlein - VP and CFO Jason Beach - VP, Finance and IR Conference Call Participants Robert Marcus - JPMorgan Lawrence Biegelsen - Wells Fargo Securities Ryan Zimmerman - BTIG Joanne Wuensch - Citibank Pito Chickering - Deutsche Bank Shagun Singh Chadha - RBC Capital Vijay Kumar - Evercore Travis Steed - Bank of America Matthew O'Brien - Piper Sandler Matt Miksic - Barclays Danielle Antalffy - UBS Matt Taylor - Jefferies Caitlin Cronin - Canaccord Sam Brodovsky - Truist Joshua Jennings - Cowen Andrew Ranieri - Morgan Stanley Operator Welcome to the First Quarter 2024 Stryker Earnings Call. My name is Christine, and I'm your operator for today's call.

Stryker Corporation (SYK) Q1 2024 Earnings Call Transcript

Stryker Corp lifted its full-year profit forecast on Tuesday, owing to resilient demand for the company's medical devices and implants.

Stryker lifts 2024 profit forecast on strong demand for medical devices, implants

The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Stryker (SYK) Q1 Earnings

Stryker (SYK) came out with quarterly earnings of $2.50 per share, beating the Zacks Consensus Estimate of $2.35 per share. This compares to earnings of $2.14 per share a year ago.

Stryker (SYK) Beats Q1 Earnings and Revenue Estimates

Stryker stock edged higher Tuesday after the company beat first-quarter expectations on the back of its medical-surgical division.

Stryker Edges Higher After Issuing A Beat-And-Raise For Its First Quarter

Portage, Michigan, April 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2024:

Stryker reports first quarter 2024 operating results

Evaluate the expected performance of Stryker (SYK) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Seeking Clues to Stryker (SYK) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Zimmer Biomet Hlds

SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.

SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?

Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings

Medtronic

Moderna

While artificial intelligence may be useful for a variety of purposes – including asking silly questions we're afraid to pose in real life – the ultimate end game for digital intelligence could be to advance the human condition, which brings us to medical AI stocks. When conducted in a controlled environment, AI can help accelerate productivity.

Medical AI Could Be Your Ticket to Riches: 3 Stocks to Buy

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

UiPath

Symbotic Inc

Robotics and related technologies, such as workflow automation products, cloud services, and generative AI technology, have captivated the investing community. They have assisted in leading the overall market higher over this past year especially.

3 Robotics Stocks to Turn $1000 into $1 Million: April 2024

Alphatec Hlds

ST. PAUL, Minn.--(BUSINESS WIRE)--Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. “The addition of Emory adds even further con.

Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

Lantheus Holdings

Insulet

ResMed

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.

5 Medical Product Stocks to Buy Amid Industry Challenges

Portage, Michigan, April 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, April 30, 2024.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter of fiscal year 2024, that ended March 31, 2024.

Stryker to announce financial results for its first quarter of fiscal year 2024

Here is how Stryker (SYK) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.

Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?

Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.

Stryker's (SYK) Latest Launch to Streamline Procedural Workflows

Portage, Michigan, March 26, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2024 Annual Meeting of Shareholders is scheduled as follows:

Stryker announces Annual Meeting of Shareholders

AMSTERDAM--(BUSINESS WIRE)--Stryker's Gamma4 system is designed to treat hip and femur fractures and streamline procedural workflows for surgeons.

Stryker launches Gamma4 Hip Fracture Nailing System in Europe

Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.

Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Reasons to Add Stryker (SYK) Stock in Your Portfolio Now

MAHWAH, N.J., USA, March 21, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a leading global medical technology company, announced today that it has completed the previously announced acquisition of SERF SAS, a France-based joint replacement company, from Menix.

Stryker completes acquisition of SERF SAS

Becton, Dickinson and Co.

Globus Medical

Intuitive Surgical

Smith & Nephew

There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.

News for Stryker Stock (SYK)